Evidence Codex is an educational reference, not medical advice. Many compounds listed are unapproved or have limited human evidence. Read the medical disclaimer.
Evidence CodexResearch, tools and practical guidance
GLP-1s & Weight Loss

Tirzepatide

← Back to Library
Label-verified Label-verified Label-verified Metabolic Incretin
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or clinical-trial above.

Overview

Route(s): Subcutaneous

Typical vial sizes: 5, 10, 15, 20, 30, 40, 50, 60 mg

Dosing window: Anytime

Receptor / target: GLP-1; GIP

Properties: Incretin

Pre-mixed: No

Unverified protocol notes

Standard Protocol

TimeframeDoseNotes
Weeks 1-42.5mg once weeklyInitiation phase. Do not skip to avoid severe GI distress.
Weeks 5-85.0mg once weeklyStandard therapeutic dose for steady fat loss.
Weeks 9-127.5mg once weeklyEscalate only if weight loss stalls.
Weeks 13-1610.0mg once weeklyAdvanced phase.
Weeks 17-2012.5mg once weeklyPre-maximum phase.
Weeks 21+15.0mg once weeklyMaximum limit. Do not exceed.

Unverified protocol note; not label dosing unless graded otherwise on this page.

Alternative: Biohacker Start

TimeframeDoseNotes
Weeks 1-41.0mg to 1.5mg once weeklyLower starting point for highly sensitive subjects.
Weeks 5-82.5mg once weeklyStandard initiation.
Weeks 9+Titrate up by 1.0mg to 2.5mg as needed.Follows standard protocol from here.

Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.

Alternative: Split Dosing

TimeframeDoseNotes
Weeks 1-41.25mg every 3.5 daysE.g., Monday and Thursday. Mitigates day-2 lethargy and day-6 appetite return.
Weeks 5-82.5mg every 3.5 daysEquals 5.0mg weekly.
Weeks 9-123.75mg every 3.5 daysEquals 7.5mg weekly.

Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.

Protocol logic check

Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; GIP); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.

Independent evidence

Approved label dosing: Zepbound starts at 2.5 mg SC once weekly for 4 weeks, then 5 mg once weekly; increases are in 2.5 mg increments after at least 4 weeks on the current dose. Weight reduction maintenance doses are 5, 10, or 15 mg weekly; maximum is 15 mg weekly.
Clinical trial regimen(s): SURMOUNT-1 studied once-weekly tirzepatide 5, 10, and 15 mg for 72 weeks.
Independent safety notes: FDA warns about adverse events from compounded semaglutide or tirzepatide doses beyond label dosing, faster titration, or more frequent dosing.

Regulatory status: approved drug label available

Storage

Refrigerate 2-8 C; do not freeze; keep in original carton away from light. Zepbound vial labeling allows room-temperature storage up to 30 C with 30-day discard rules.

Contraindications (limited evidence)

  • Personal or family history of Medullary Thyroid Carcinoma (MTC). Limited / unverified
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Limited / unverified
  • Personal or family history of thyroid C-cell tumors. Limited / unverified
  • Active or history of acute pancreatitis. Limited / unverified
  • Severe gastroparesis or clinically significant delayed gastric emptying. Limited / unverified
  • Type 1 diabetes mellitus. Limited / unverified
  • Diabetic ketoacidosis. Limited / unverified
  • Pregnancy: discontinue at least 2 months prior to planned conception; fetal risk not established. Limited / unverified
  • Breastfeeding: insufficient safety data. Limited / unverified
  • Known hypersensitivity or anaphylaxis to tirzepatide or any formulation excipient. Limited / unverified
  • Concurrent use with any other GLP-1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide): direct pharmacological overlap. Limited / unverified
  • Concurrent use with retatrutide, mazdutide, survodutide, or any other incretin agonist: additive receptor conflict. Limited / unverified
  • History of suicidal ideation or prior suicide attempts: monitor closely. Limited / unverified
  • Planned general anesthesia or elective surgery: delayed gastric emptying significantly raises pulmonary aspiration risk; follow pre-operative fasting and discontinuation protocols. Limited / unverified
  • Severe inflammatory bowel disease or active Crohn's disease: GI motility impairment may worsen symptoms. Limited / unverified
  • End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution. Limited / unverified
  • Pediatric use under age 18: safety and efficacy not established. Limited / unverified

Side effects (limited evidence)

  • Nausea: most common adverse effect; typically peaks in the first 4 weeks of each dose escalation. Limited / unverified
  • Diarrhea. Limited / unverified
  • Vomiting. Limited / unverified
  • Constipation. Limited / unverified
  • Abdominal pain and cramping. Limited / unverified
  • Dyspepsia (indigestion). Limited / unverified
  • Abdominal distension and bloating. Limited / unverified
  • Decreased appetite and dysgeusia (altered taste). Limited / unverified
  • Belching and flatulence. Limited / unverified
  • Gastroparesis: delayed gastric emptying; may persist even with pre-operative fasting. Limited / unverified
  • Gastroesophageal reflux disease (GERD) exacerbation. Limited / unverified
  • Fatigue and lethargy: frequently secondary to acute caloric deficit. Limited / unverified
  • Day-2 post-injection lethargy: commonly reported phenomenon, particularly in the 12-36 hour window following injection. Limited / unverified
  • Headache. Limited / unverified
  • Dizziness. Limited / unverified
  • Hypoglycemia: risk elevated when combined with insulin or sulfonylureas; rare when used as monotherapy. Limited / unverified
  • Acute pancreatitis: documented in case reports; causal relationship under ongoing investigation. Limited / unverified
  • Acute kidney injury: primarily mediated by dehydration from GI side effects. Limited / unverified
  • Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and rate of weight loss. Limited / unverified
  • Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction. Limited / unverified
  • Thyroid C-cell tumor risk: confirmed in rodent models; human risk remains under evaluation; monitor for neck mass, hoarseness, or dysphagia. Limited / unverified
  • Alopecia (hair loss): reported in post-marketing surveillance. Limited / unverified
  • Injection site reactions: redness, itching, bruising at administration site. Limited / unverified
  • Anaphylaxis and angioedema: rare but documented. Limited / unverified
  • Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying. Limited / unverified
  • Rapid weight regain upon discontinuation: without lifestyle intervention, significant weight rebound is expected within months of cessation. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

CagrilintideAOD-96045-Amino-1MQ

Reported contraindicated combinations:

SemaglutideRetatrutideMazdutideSurvodutideLiraglutideCagriSema (Cagrilintide + Semaglutide)

Sources